Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Inovio Pharmaceuticals Inc (INO) vs RUM Group Inc. Class A Common Stock (RUM) Price & Performance

Inovio Pharmaceuticals IncTrade
RUM Group Inc. Class A Common StockTrade

Price performance (Past 24H)

Key statistics

Inovio Pharmaceuticals Inc vs RUM Group Inc. Class A Common Stock — how do they compare? Inovio Pharmaceuticals Inc trades at $0.96 (market cap $103.19M), while RUM Group Inc. Class A Common Stock trades at $6.02 (market cap $2.68B). The key difference: RUM Group Inc. Class A Common Stock is far larger — about 26× Inovio Pharmaceuticals Inc's market cap, and Inovio Pharmaceuticals Inc is more actively traded (8,461,580 versus 3,201,203). Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and RUM Group Inc. Class A Common Stock for 0 Days on average.

INORUM
Market Cap
$103.19M$2.68B
Volume
8,461,5803,201,203
Sector
HealthMedia
52-Week High
$2.60$10.23
52-Week Low
$0.66$4.67
Typical Hold Time
43 Days0 Days
Enterprise Value
$74.52M$2.98B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals (INO) trades at $0.986, down 10.77% in the last session, with a bearish technical signal from moving averages. The company shows consistent quarterly earnings beats but operates with minimal revenue ($65K in 2025) and significant losses (-$85M net income). Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis. Analyst consensus remains positive with a $2.75 price target despite negative profitability metrics.

The stock presents high-risk biotech speculation with potential upside dependent on FDA approval. Current valuation metrics (P/S 961.51) reflect speculative optimism rather than fundamentals. Major risks include cash burn (-$21.5M net cash flow), regulatory uncertainty, and competitive pressures. Successful commercialization of INO-3107 is critical for viability.

RUM Group Inc. Class A Common Stock

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

INO
97% Buy3% Sell
Avg holding period · 43 Days
RUM
100% Buy0% Sell
Avg holding period · 0 Days

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO →

About RUM Group Inc. Class A Common Stock

RUM Group Inc., formerly Rumble Inc., is a holding company operating two business units: Rumble, an online video-sharing platform, and Quake AI, a cloud computing and artificial-intelligence infrastructure business.

Read more on RUM →